1 Nicotinylalanine, an inhibitor of kynurenine metabolism, has been shown to elevate brain levels of endogenous kynurenic acid, an excitatory amino acid receptor antagonist. This study examined the potential of nicotinylalanine to in¯uence excitotoxic damage to striatal NADPH diaphorase (NADPH-d) and g-aminobutyric acid (GABA)ergic neurones that are selectively lost in Huntington's disease. 2 A unilateral injection of the N-methyl-D-aspartate (NMDA) receptor agonist, quinolinic acid, into the rat striatum produced an 88% depletion of NADPH-d neurones. Intrastriatal infusion of quinolinic acid also produced a dose-dependent reduction in striatal GABA content. 3 Nicotinylalanine (2.3, 3.2, 4.6, 6.4 nmol 5 ml 71 , i.c.v.) administered with L-kynurenine (450 mg kg 71 ), a precursor of kynurenic acid, and probenecid (200 mg kg 71 ), an inhibitor of organic acid transport, 3 h before the injection of quinolinic acid (15 nmol) produced a dose-related attenuation of the quinolinic acid-induced loss of NADPH-d neurones. Nicotinylalanine (5.6 nmol 5 ml 71 ) in combination with Lkynurenine and probenecid also attenuated quinolinic acid-induced reductions in striatal GABA content. 4 Nicotinylalanine (4.6 nmol, i.c.v.), L-kynurenine alone or L-kynurenine administered with probenecid did not attenuate quinolinic acid-induced depletion of striatal NADPH-d neurones. However, combined administration of kynurenine and probenecid did prevent quinolinic acid-induced reductions in ipsilateral striatal GABA content. 5 Injection of nicotinylalanine, at doses (4.6 nmol and 5.6 nmol i.c.v.) which attenuated quinolinic acid-induced striatal neurotoxicity, when combined with L-kynurenine and probenecid produced increases in both whole brain and striatal kynurenic acid levels. Administration of L-kynurenine and probenecid without nicotinylalanine also elevated kynurenic acid, but to a lesser extent. 6 The results of this study demonstrate that nicotinylalanine has the potential to attenuate quinolinic acid-induced striatal neurotoxicity. It is suggested that nicotinylalanine exerts its eect by increasing levels of endogenous kynurenic acid in the brain. The results of this study suggest that agents which in¯uence levels of endogenous excitatory amino acid antagonists such as kynurenic acid may be useful in preventing excitotoxic damage to neurones in the CNS.
Introduction
The enzymatic metabolism of tryptophan in the central nervous system (CNS) via the kynurenine pathway yields several intermediates that have the ability to in¯uence excitatory amino acid (EAA) neurotransmission (Schwarcz et al., 1984) . One such product, quinolinic acid, a pyridine dicarboxylic acid, behaves as an agonist at N-methyl-Daspartate (NMDA) receptor sites; another, kynurenic acid, acts as an EAA receptor antagonist. Neuronal application of quinolinic acid produces excitatory responses (Stone & Perkins, 1981) and its focal injection in brain areas causes excitotoxic damage to neurons bearing NMDA receptors and receiving glutamatergic innervation (Schwarcz, 1983; Schwarcz et al., 1984; El-Defrawy et al., 1985) . In contrast, kynurenic acid blocks excitatory responses produced by NMDA and non-NMDA receptor agonists (Perkins & Stone, 1982) , and prevents the excitotoxic eects of quinolinic acid (Foster et al., 1984; Boegman et al., 1985; Winni et al., 1991; Cockhill et al., 1992) .
Both quinolinic acid and kynurenic acid are derived from the catabolism of kynurenine, the ®rst metabolic product of tryptophan degradation via the kynurenine pathway. The synthesis of kynurenic acid is catalyzed by kynurenine aminotransferase, while quinolinic acid is produced from kynurenine via the activity of three enzymes: kynureninase, kynurenine hydroxylase and 3-hydroxyanthranilic acid oxygenase. Recent studies have shown that in the CNS production of kynurenines, including kynurenic acid and quinolinic acid, occurs primarily in glial cells (Roberts et al., 1992; Schwarcz, 1993) .
Since quinolinic acid originates in the CNS and can cause profound neuronal damage, it has been designated as an endogenous excitotoxin (Schwarcz et al., 1984) . The phenomenon of excitotoxicity, involving neuronal damage due to overstimulation of NMDA and non-NMDA ionotropic receptors has been implicated in acute neuronal disorders such as stroke, and chronic disorders such as Huntington's disease and Parkinson's disease (Rothman & Olney, 1986; Choi, 1988) . In contrast to quinolinic acid, an EAA receptor agonist, kynurenic acid can be designated as an endogenous EAA receptor antagonist. As both are derived from a common precursor (kynurenine) and exert opposite actions on neuronal viability, a balance between these metabolites in the CNS may in¯uence neuronal survival. Indeed, it has been shown that kynurenic levels are depleted in the striatum and cortex of patients with Huntington's disease (HD) and the neuronal pathology produced by the intrastriatal infusion of quinolinic acid closely mimics that found in HD (Beal et al., 1986) . Thus, a pharmacological strategy that increases kynurenic acid levels in the CNS could potentially inhibit the neuronal loss that results from excessive stimulation of NMDA receptors. The recent discovery that certain agents can elevate levels of endogenous kynurenic acid in the brain makes it possible to evaluate this strategy in experimental models of excitotoxic damage.
One of the agents that elevates brain kynurenic acid level is nicotinylalanine, a structural analogue of kynurenine and inhibitor of the enzymes kynureninase and kynurenine hydroxylase (Decker et al., 1963) . Administration of nicotinylalanine to rats, in combination with L-kynurenine and probenecid, compounds which act as a precursor of kynurenic acid and block its egress from the brain, respectively , produces a signi®cant increase in brain kynurenic acid content (Moroni et al., 1991; Russi et al., 1992; Miranda et al., 1997) . Nicotinylalanine was also shown to reduce the incidence of chemical seizures, an eect which has been attributed to its ability to augment brain kynurenic acid (Connick et al., 1992) . Nicotinylalanine, through its ability to increase endogenous kynurenic acid levels in the CNS, might be expected to inhibit excitotoxic damage. Indeed, it has been demonstrated that nicotinylalanine in combination with Lkynurenine and probenecid can attenuate quinolinic acidinduced excitotoxicity in the substantia nigra pars compacta (Miranda et al., 1997) . However, the potential of nicotinylalanine to in¯uence excitotoxic damage in the striatum, has not been explored. The goal of this study was to investigate if nicotinylalanine, administered under conditions which lead to increased brain kynurenic acid, in¯uences excitotoxic damage to speci®c populations of striatal neurones. This goal was addressed by evaluating the eects of centrally administered nicotinylalanine on the survival of striatal NADPH-diaphorase (NADPH-d) neurones and striatal GABA content, a marker of GABAergic neuronal viability, following a toxic injection of quinolinic acid into the rat striatum. Previous work in this and other laboratories has demonstrated that these neuronal populations are readily destroyed by intrastriatal quinolinic acid injections (Beal et al., 1986; Boegman & Parent, 1988; Davies & Roberts, 1987; Roberts et al., 1993; Kalisch et al., 1994) . To optimize the action of nicotinylalanine, this agent was co-administered with L-kynurenine, the precursor of kynurenic acid and probenecid, an inhibitor of organic acid transport, which reduces the eux of kynurenic acid from the brain (Moroni et al., 1991; Miller et al., 1992; Vescei et al., 1992) .
Methods
Male Sprague-Dawley rats (Charles River, St. Constant, Quebec), weighing between 125 ± 150 g, were given free access to food (Purina rat chow) and drinking water. Experiments described here were performed in accordance with the Guidelines of the Canadian Council on Animal Care using protocols approved by Queen's University Animal Care Committee.
Surgery and stereotaxic injections
Animals were anaesthetized with a 4% halothane-96% oxygen mixture and positioned in a Narashighe small animal stereotaxic apparatus. The skull was exposed and a small hole drilled for placement of an intraventricular cannula (0.18 min i.d.; 0.36 mm, o.d., 2 cm long). Following insertion into the lateral ventricle, the cannula was connected to a Hamilton syringe ®lled with normal saline or a nicotinylalanine solution and mounted in an infusion pump. The saline or nicotinylalanine solution (2.3 ± 6.4 nmol) was infused (5 ml volume) into the lateral ventricle over a 100 second period. In order to prevent back¯ow of nicotinylalanine, the cannula was left in place for 2 min to allow nicotinylalanine to diuse away and then be removed. Injections of L-kynurenine (450 mg kg 71 ) and probenecid (200 mg kg 71 ) were then administered by the intraperitoneal route. Control animals received injections of saline over the same time period. Both L-kynurenine and probenecid were dissolved in 1 N NaOH and titrated to pH=10 with 1 N HCl.
Three hours following drug treatment a single unilateral injection of quinolinic acid (15 nmol in 0.5 ml saline or 30 nmol in 1 ml) was delivered into the right striatum. Brie¯y, the animal was placed in a stereotaxic frame, the skull exposed and a small hole drilled by use of the coordinates: 1.0 mm anterior to bregma, 3.2 mm lateral to midline and 5.0 mm ventral to the skull surface with incisor bar set at 73.3 mm. The intrastriatal injection was delivered over a 75 s period and the injection cannula was left in place for an additional 2 min to prevent the back¯ow before its removal. Control animals received normal saline instead of quinolinic acid.
Two days following the intrastriatal injection, the animals were anaesthetized and prepared for ®xation of brain tissue as described in a previous study (Kalisch et al., 1994) . The ®xed brain was sectioned in a coronal plane using a cryostat and tissue slices (40 mm thickness) were collected in culture plates containing 0.9% saline. The sections incorporating the striatum were subsequently stained to visualize NADPHdiaphorase neurones by use of a modi®cation of the method described by Sims et al. (1974) . Brie¯y, tissue sections in which the injection cannula tract was clearly visible, and those anterior and posterior to the cannula, were incubated in phosphate buered saline containing 1.4 mM NADH, 1.1 mM nitroblue tetrazolium and 12% dimethylsulphoxide for 15 ± 30 min and subsequently rinsed twice with saline. Sections were mounted on glass slides and coverslips applied. Cells staining positive for NADPH-d in the striatum within a de®ned area (1.6 mm61.0 mm), which included the tip of the infusion cannula track, were counted under bright ®eld illumination. For each animal, three tissue sections containing the cannula tract were counted. All histological slides used in cell counts were coded to mask the treatment condition of the animal from which the tissue section was obtained. The pooled total of cell counts for the injected side in each animal was expressed as a percentage of the total of cell counts at the corresponding site on the contralateral (uninjected) striatum.
Kynurenic acid measurements
In a separate group of saline-or drug-treated animals, whole brain kynurenic acid levels were measured by use of a modi®cation of a method described by Russi et al. (1992) . Three hours following central injection the whole brain from each animal was homogenized in an ethanol-0.1 M NaOH mixture (3 : 1). The homogenate was centrifuged (10 min, 50006g) and the pellet resuspended in 5 ml of 90% ethanol. The supernatants were pooled and placed overnight at 7808C to precipitate fatty materials which were discarded after centrifugation (20006g for 5 min). Following this, 200 ± 300 mg of an ion exchange resin (Dowex AG1 WX8, acetate form, 100 ± 200 mesh) were added to the supernatant and the mixture centrifuged for 5 min. The supernatant was discarded, the resin suspended in 2 ml of water and placed in glass columns (pasteur pipettes) plugged with glass wool. The column was washed with 5 ml of water and with 10 ml of 1 N formic acid. Kynurenic acid was eluted with 5 ml 1 N formic acid. This eluate was mixed with 250 ± 300 mg of Dowex AG-5 WX8 resin, in the H + form centrifuged at 20 0006g for 5 min and the pellet resuspended in 2 ml of water and placed in the pasteur pipette. Kynurenic acid was eluted with 5 ml 3 N NH 4 OH. The eluate was concentrated to dryness and resuspended in 200 ml of sodium acetate buer (pH 6.2), and 50 ml injected into the high performance liquid chromatographic (h.p.l.c.) system. The h.p.l.c. utilized a mobile phase consisting of 4.5% acetonitrile and 50 mM sodium acetate (pH=6.2). The mobile phase was pumped through a reverse phase column (CSC-spherisorb-ODS2, 10 cm60.46 cm, 3 mm particle size) at a¯ow rate of 1.0 ml min 71 . A solution of zinc acetate (0.5 M) was delivered post-column to enhance the detection of kynurenic acid by a¯uorescence detector (Shimadzu RF-551) set at excitation and emission wavelengths of 344 and 398 nm, respectively. The peak areas of the chromatographic signal were integrated. Kynurenic acid standards and a sodium acetate blank were analysed with each set of experimental samples and a standard curve was generated. The detection limit of this assay was 35 fmol.
In another group of animals that had been pretreated with L-kynurenine (450 mg kg 71 , i.p.) and probenecid (200 mg kg 71 , i.p.) with or without intraventricular nicotinylalanine (5.6 nmol), the whole striatum from each animal was dissected out at 1.5, 3, 6 and 9 h post treatment. The content of kynurenic acid in the striatal tissue was measured with the procedure described above.
Striatal GABA content
In a separate group of animals, the ability of nicotinylalanine to in¯uence quinolinic acid-induced reduction in striatal GABA content was evaluated. The animals were decapitated and the brain rapidly removed washed with ice cold saline and placed in a brain mould. A 2 mm slice of striatum from each animal was dissected out and a 2 mm diameter punch at the tip of the cannula track was homogenized in 500 ml of nanopure water and centrifuged at 50006g for 30 min. Striatal GABA content was assayed by h.p.l.c. Brie¯y, 200 ml of the supernatant was derivitized by mixing with 200 ml of o-phthaldialdehyde reagent solution before application to a reverse phase column (LC-18-Supelcosil, 15 cm64.6 mm, 5 mm particle size). A portion (100 ml) of the supernatant was retained for protein determination (Bradford, 1976) . The mobile phase consisted of 0.04 M sodium acetate buer with 30% methanol (pH=7.5). GABA was detected with a Shimadzu RF-590 uorescence detector at an excitation wavelength of 345 and a detection wavelength of 470. In order to determine GABA concentrations a standard curve was constructed for each assay. The detection limit of this assay was 1 pmol. GABA content in the ipsilateral striatum was expressed as a percentage of that in the contralateral side.
Statistical analyses
The data were compared by a one way analysis of variance (ANOVA), followed by Newman-Keul's test to determine dierences between various drug treatments. Dierences in mean values were considered signi®cant at P50.05. Figure 1 shows the eect of saline and quinolinic acid (15 nmol) on the survival of the NADPH-d neurones 2 days after a single injection into the striatum. The data, expressed as % cell survival, represent the number of NADPH-d neurones on the injected side as a % of cells in corresponding area of the contralateral uninjected striatum. The total cell counts in designated area of the uninjected side were 99.3+5.4 (saline group) and 105.3+8.2 (quinolinic acid group). Following intrastriatal saline (0.5 ml) there was over 90% survival of NADPH-d neurones. In contrast, injection of quinolinic acid (15 nmol) produced a severe neuronal depletion with only 12% of NADPH-d neurones surviving in the injected side. This eect of quinolinic acid was very reproducible (see below).
Results
To investigate the action of nicotinylalanine on quinolinic acid-induced toxicity, this agent was injected into the lateral ventricle 3 h before an intrastriatal quinolinic acid (15 nmol) injection. L-Kynurenine (450 mg kg 71 , i.p.) and probenecid Figure 1 The eect of a unilateral intrastriatal injection of saline (0.5 ml) or quinolinic acid (Quin, 15 nmol, 0.5 ml) on the survival of neurones staining for NADPH-d diaphorase in the rat striatum. Values shown (mean+s.e.mean) represent cell counts in the Quininjected side expressed as percentage of cells in a corresponding area of the striatum on the uninjected side in the same animal; n=4 animals. *P50.001, value signi®cantly dierent from saline-injected animals.
(200 mg kg 71 , i.p.) were co-administered by the i.p. route immediately after the nicotinylalanine injection. As shown in Figure 2 , central injection of nicotinylalanine (2.3 ± 6.4 nmol) and co-treatment produced a dose-dependent increase in the survival of NADPH-d neurones in the quinolinic acid-injected side. In animals receiving the highest dose (6.4 nmol) of the drug, approximately 72% of neurones in the injected striatum survived quinolinic acid toxicity. Statistical analysis con®rmed a signi®cant treatment eect. Thus, centrally injected nicotinylalanine with the co-treatment aorded protection against quinolinic acid-induced neurotoxicity.
To determine if nicotinylalanine or co-treatment alone had the ability to in¯uence quinolinic acid toxicity, drugs were injected separately and their action on toxicity examined in similar experiments. The treatments evaluated were: saline , and L-kynurenine in combination with probenecid. Each evaluation included a control group of animals which received the treatment under study but was administered intrastriatal saline (0.5 ml) instead of quinolinic acid (15 nmol). As shown in Figure 3 , after an injection of intrastriatal saline, the survival of NADPH-d neurones ranged between 89 and 94%. This eect was similar to that observed in the preceding experiments (Figure 1 ). Intrastriatal quinolinic acid, nicotinylalanine alone or the L-kynurenine-probenecid combination did not in¯uence quinolinic acid toxicity. In the quinolinic injected acid groups, the NADPH-d neurone survival ranged between 8 ± 17%, values which were similar to that obtained with quinolinic acid in untreated animals (Figure 1) . Thus, none of the treatments evaluated in this part of the study exerted an anti-quinolinic acid action comparable to that observed with nicotinylalanine, in combination with Lkynurenine and probenecid (Figure 2) .
In order to validate further the neuroprotective actions of nicotinylalanine, its ability to in¯uence quinolinic acid-induced reductions in striatal GABA content was assessed. Striatal GABA content in the injection side, expressed as a percentage of that from the intact side, was used as a biochemical marker of the viability of the GABAergic projection neurones ( Figure  4 ). Focal infusion of saline into the striatum did not signi®cantly alter GABA content in the ipsilateral striatum. However, intrastriatal infusion of quinolinic acid resulted in dose-dependent reductions in ipsilateral GABA content (P50.05). In rats infused with the lowest dose of quinolinic acid, ipsilateral striatal GABA content was 64+13.5% of the contralateral side. At the highest concentration of quinolinic acid employed in this study (240 nmol), ipsilateral striatal GABA content was 27.8+5.3% of the contralateral side. In subsequent experiments the dose of quinolinic acid (30 nmol) that produced approximately 50% reduction in striatal GABA content was selected to examine the eect of nicotinylalanine on quinolinic acid-induced excitotoxic response.
As illustrated in Figure 5 , injection of quinolinic acid kynurenine with nicotinylalanine (5.6 nmol 5 ml 71 , i.c.v.) also did not signi®cantly alter the magnitude of quinolinic acidinduced striatal GABA depletion. However, when animals were pretreated with the L-kynurenine/probenecid combination in the absence of nicotinylalanine, intrastriatal injection of quinolinic acid produced a 19% decrease in GABA; addition of nicotinylalanine to this combination resulted in 8% decrease in GABA content. A statistical comparison revealed a signi®cant eect of these two sets of treatment on the quinolinic acid-induced depletion of striatal GABA observed in untreated animals ( Figure 5 . Thus, combined administration of L-kynurenine and probenecid with or without nicotinylalanine signi®cantly inhibited the quinolinic acid-induced excitotoxic response.
The eects of nicotinylalanine (4.6 nmol 5 ml
71
) and cotreatment with L-kynurenine and probenecid on the content of brain kynurenic acid is represented in Figure 6 . In untreated animals, the levels of kynurenic acid was 42.1+20 pmol g 71 . Administration of L-kynurenine plus probenecid raised the level to 3778+519 pmol g 71 . However, when this combination was delivered with nicotinylalanine (4.6 nmol, i.c.v.) the level of kynurenic acid rose to 5638+1203 pmol g 71 . This value was signi®cantly greater than that obtained after all other treatments used in this part of the study. The eects of nicotinylalanine (5.6 nmol) on striatal levels of kynurenic acid are presented in Figure 7 . The level of kynurenic acid in the striatum of untreated animals was 964+240 pmol g 71 tissue (n=5). Following L-kynurenine and probenecid treatment produced a 2 fold increase, while addition of nicotinylalanine produced an almost 4 fold increase in kynurenic acid levels. This increase in the nicotinylalanine group was signi®cantly dierent from that in the untreated group and L-kynurenine/ probenecid-treated group at the three hour post-injection period (P50.05) but not at subsequent time periods.
Discussion
The results of this study demonstrate that a unilateral injection of quinolinic acid into the rat striatum leads to a severe depletion of NADPH-d neurones and a reduction in striatal GABA content. Nicotinylalanine, an inhibitor of kynurenine metabolism, elevated the brain level of endogenous kynurenic acid, a broad spectrum EAA receptor antagonist, and signi®cantly attenuated the neurotoxic action of quinolinic acid on NADPH-d neurones and GABA containing neurones.
In this study, conditions for the expression of the action of nicotinylalanine were optimized by selection of a highly sensitive model of toxicity, and by administration of cotreatments which would favour accumulation of endogenous kynurenic acid in the brain. The NADPH-d neurones of the rat striatum have been found in previous work to be highly sensitive to the action of quinolinic acid (Boegman & Parent, 1988; Kalisch et al., 1994) . Indeed, an almost complete loss of striatal NADPH-d neurones in the injected area could be produced with a relatively low dose of quinolinic acid. GABA containing neurones in the striatum have also been found to be Dierences between groups were determined by ANOVA followed by Dunnett's post-hoc test to determine dierences from saline treated rats (P50.05). *Represents a statistically signi®cant dierence from saline-treated animals.
sensitive to quinolinic acid-induced toxicity (Santamaria et al., 1996) . Thus, the fact that striatal cholinergic and non-striatal cholinergic and dopaminergic neurones, although vulnerable to quinolinic acid, are less sensitive to its toxic action (Schwarcz et al., 1983; El Defrawy et al., 1985; Connop et al., 1995) and the sensitivity of the NADPH-d neurones and GABA containing neurones to quinolinic acid, coupled with the reproducibility of the eects of quinolinic acid action, in¯uenced the choice of this model. The use of this model was based on the previous ®ndings showing that kynurenine which acts as the source of kynurenic acid, and probenecid, which blocks organic acid transport and thus reduces egress from the brain, can elevate levels of endogenous kynurenic acid in the brain (Moroni et al., 1991; Miller et al., 1992) .
The anti-neurotoxic action of nicotinylalanine observed most likely results from elevation of endogenous brain kynurenic acid (KA) and subsequent blockade of quinolinic acid (QA)-sensitive NMDA receptors. This explanation is favoured by previous observations that exogenous KA readily blocks the biochemical and behavioural manifestations of QA neurotoxicity (Foster et al., 1984; Boegman et al., 1985; Wirsching et al., 1989; Winn et al., 1991; Cockhill et al., 1992) , and that the administration of nicotinylalanine elevates endogenous KA in the brain (Moroni et al., 1991) . In the present study administration of a dose of nicotinylalanine (delivered in combination with L-kynurenine and probenecid) which blocked QA-induced toxicity in two neuronal populations also produced a very large increase in whole brain KA and an almost 2 fold increase in striatal KA. The protection against QA-induced toxicity aorded by the administration of nicotinylalanine in combination with L-kynurenine and probenecid, in spite of only a modest increase in striatal KA when compared to that in whole brain is surprising. However, KAT, the enzyme catalyzing KA synthesis, is found in astrocytes surrounding excitatory synapses in the striatum (Roberts et al., 1995) and thus, KA levels may be greatly increased in the synapse when compared to the surrounding tissue. Previous microdialysis experiments have shown that treatments which elevate endogenous brain KA can also increase its eux Wu et al., 1992; Carpenedo et al., 1994) . However, the relationship between the tissue content of endogenous KA and its availability at the synapse is not well understood. A study of this relationship including the measurement of synaptic concentrations of KA may reveal the extent to which tissue KA must be augmented to produce a neuroprotective eect. Rats administered nicotinylalanine, L-kynurenine and probenecid or the combination of kynurenine and probenecid alone appeared to be sedated. These eects were more pronounced in the nicotinylalanine, kynurenine and probenecid treatment group (experimental observations) and may re¯ect the higher synaptic concentrations of KA achieved in this treatment group.
Interestingly, combined administration of L-kynurenine and probenecid also provided a signi®cant increase in whole brain KA. Although unable to prevent QA-induced depletions in NADPH-d neurones, this combination attenuated QAinduced reductions in striatal GABA content. The inability of . Dierences between groups were determined by use of ANOVA followed by Dunnett's post-hoc test to determine signi®cant dierences from saline treated animals. Each point represents the mean of 3 ± 9 determinations; vertical lines show s.e.mean. *Represents a signi®cant dierence from control (P50.05).
L-kynurenine and probenecid in the absence of nicotinylalanine to protect NADPH-d neurones may indicate that these neurones are less sensitive to the actions of KA than are GABA containing neurones. Alternatively, the inability of the combination of L-kynurenine and probenecid to protect against QA-induced destruction of NADPH-diaphorase neurones may re¯ect relatively poor synthesis of KA in synapses surrounding these neurones. Indeed, as KAT is found in astrocytes surrounding excitatory synapses in the striatum (Roberts et al., 1995) and GABA-containing neurones are the target for the majority of glutamatergic aerents from the cortex, it is possible that KA levels at synapses surrounding GABA neurones exceed that at NADPH-d neurones. It is also likely that the dierential ability of endogenous KA against QA-induced excitotoxicity in the striatum re¯ects dierences in the expression of NMDA receptor subtypes on GABA-containing neurones relative to NADHP-diaphorase neurones. However, at present no evidence exists for a dierential eect of KA on QA-induced toxicity in the striatum.
In contrast to the ®ndings of Santamaria et al. (1996) , administration of L-kynurenine or probenecid alone in this study did not protect against QA-induced reductions in striatal GABA content. These results are surprising, given that the concentration of QA employed in this study (30 nmol) is quite low compared to that used by Santamaria et al. (1996) (240 nmol). The reason for the discrepancy between the results of this study and that of Santamaria et al. (1996) are unknown. However, in support of the present data a recent study found that probenecid alone was unable to suppress NMDA-evoked responses in striatal neurones in vivo (Urenjak et al., 1997) . The authors of this study suggest that inhibition of organic anion transport alone is not sucient to protect against toxicity associated with excessive NMDAreceptor activation (Urenjak et al., 1997) . The absence of protection following the administration of L-kynurenine can be explained by the fact that L-kynurenine (450 mg kg 71 , i.p.) while signi®cantly increasing the concentration of KA in the striatum (Vescei et al., 1992) , also increases the concentration of QA in the brain (Luthman et al., 1996) . It has been shown that brain tissue has the capacity to retain QA while KA can be removed from the brain through an organic acid transporter (Vescei et al., 1992; Speciale et al., 1993) . Thus, administration of L-kynurenine in the absence of nicotinylalanine or probenecid most likely increases the concentration of QA in the brain and thus counteracts the neuroprotective eects of elevated endogenous KA. The administration of nicotinylalanine and L-kynurenine was unable to prevent QAinduced depletions of NADPH-d and GABA containing neurones. It has been suggested that enzymatic degradation of KA does not play a signi®cant role in the removal of KA from the brain and the majority of KA in the brain is eliminated via the probenecid sensitive organic acid transporter (Stone, 1993) . The absence of protection in this treatment group appears to con®rm this hypothesis, as in the absence of probenecid it is likely that KA leaves the brain and the concentration of KA in the synapse is insucient to antagonize QA-induced toxicity.
It is possible that the eects on GABA content in the various treatment groups are due to non-speci®c eects on GABA synthesis and degradation. Thus, the neuroprotection in the present study may have been the result of an increase in GABA synthesis or a decrease in GABA degradation. However, histological studies have con®rmed that QA is toxic to GABA-containing neurones in the striatum (FigueredoCardenas et al., 1994) , suggesting that QA-induced depletions in striatal GABA content are a result of the destruction of GABA-containing neurones and not a result of eects on GABA synthesis or degradation. In addition, probenecid and L-kynurenine alone or L-kynurenine and nicotinylalanine did not have any eect on QA-induced reductions in striatal GABA content. Thus, it is unlikely that the preservation of GABA levels in the groups pretreated with kynuerenine and probenecid with or without nicotinylalanine before the infusion of QA are due to non-speci®c eects.
The possibility of a direct action of nicotinylalanine on NMDA receptors was excluded by its failure to in¯uence QAinduced depletion of NADPH-d neurones when administered in the absence of co-treatment. Nicotinylalanine itself also failed to elevate KA level. This lack of eect of nicotinylalanine on its own may arise from a lack of precursor availability for KA synthesis and/or a rapid removal of KA from the brain.
Although administration of nicotinylalanine in combination with L-kynurenine and probenecid produced a large increase in brain KA, blockade of QA-induced destruction of NADPH-d neurones was incomplete. Exogenous KA, when co-injected locally with QA, has been found to produce a complete blockade of QA toxicity . A local injection has the potential to produce high levels of extracellular KA at the target sites. However, such levels may not be achieved with agents that produce a global in vivo increase in endogenous KA. Indeed as stated previously, the production of kynurenine metabolites in the brain occurs mainly in synapses surrounding excitatory synapses (Roberts et al., 1995) . Thus, to be pharmacologically eective the endogenous KA produced in astrocytes must diuse to neuronal cell bodies and block the EAA receptors located on their surface. It is likely that despite the use of probenecid a signi®cant portion of synthesized KA is dissipated by diusion or non-speci®c binding and is less available to such receptors. Thus, endogenously produced KA may be less eective than exogenous KA injected in the vicinity of receptors.
The metabolism of kynurenine is also known to yield several other products (quinaldic, hydroxy quinaldic and xanthurenic acid) which are structurally rated to KA and some of which act as EAA antagonists. However, in comparative studies on the pharmacological eects of these products, KA has been shown to be the most potent (Perkins & Stone, 1982; Robinson et al., 1985; Jhamandas et al., 1990) . Also, the extent to which these agents are produced in the brain is presently unclear. Thus, endogenous KA is likely to be a major contributor to the observed anti-QA action of nicotinylalanine, although potential contributions from other less active antagonist metabolites to this action cannot be overlooked. The relationship between endogenous KA and cell survival in the CNS remains to be explored further.
The present ®ndings, indicating a potential role of endogenous KA as an anti-neurotoxic agent, suggest a novel strategy of neuronal protection from an excitotoxic insult. Excitotoxicity has been implicated in diverse conditions such as brain hypoxia/ischaemia, hypoglycaemia, status epilepticus and chronic neurodegenerative disease (Olney, 1990) . Thus, agents that produce optimal elevation of endogenous EAA receptor antagonists in the CNS may prove useful as novel neuroprotectants.
